期刊文献+

化疗及放化疗联合治疗局部晚期非小细胞肺癌的临床研究 被引量:1

Clinical Study of Chemotherapy and Chemoradiotherapy for the Treatment of Local Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 【目的】比较单纯化疗与放化疗联合治疗局部晚期非小细胞肺癌(NSCLC)的疗效及毒性反应。【方法]56例不能手术的局部晚期NSCLC患者按治疗方法不同分为单纯化疗组31例(A组),放化疗联合组25例(B组),对比两组疗效及安全性。【结果】治疗有效率、中位生存期及1、3年生存率A组分别为38.7%、8.8个月、29%和0,B组分别为68%、13.5个月、56%和8%,B组较A组明显提高,差异有显著性(P〈0.05)。白细胞减少、血小板减少及消化道反应A组发生率分别为48.4%、16.1%和71%,B组分别为72%、20%和80%,两组相比差异均无显著性(P〉0.05)。【结论】对不能手术的局部晚期NSCLC采用放化疗联合治疗优于单纯化疗,且毒副反应能耐受。 [Objective] To compare the efficacy and toxic reaction of single chemotherapy vs. chemoradio- therapy for the treatment of local advanced non small cell lung cancer(NSCLC). [Methods] Totally 56 patients with local advanced NSCLC who could not undergo the operation were divided into single chemotherapy group(group A, n =31) and chemoradiotherapy group(group B, n --25) according to different therapy meth ods. The efficacy and safety were compared between two groups. [Results] The effective rate, median survival, 1-year survival rate and 3-year survival rate in the group A were 38.7%, 8.8 mouths, 29% and 0, respectively, which were higher than those in the group B(68%, 13. 5 months, 56% and 8%, respectively), and there were significant differences ( P 〈0. 05). The incidence of leucopenia, thrombocytopenia and digestive tract reaction in group A were 48.4%, 16. 1% and 71%, respectively, while those of group B were 72%, 20% and 80%, respectively, and there were no significant differences between two groups (P 〉 0. 05). [Conclusion] Chemoradiotherapy for the treatment of local advanced NSCI.C is more effective than simple chemotherapy, and its toxic reactions can be tolerated.
作者 龚乐明
出处 《医学临床研究》 CAS 2011年第1期92-93,96,共3页 Journal of Clinical Research
关键词 非小细胞肺/药物疗法 非小细胞肺/放射疗法 carcinoma,non-small-cell lung/BT carcinoma,non small cell lung/RA
  • 相关文献

参考文献6

二级参考文献58

  • 1王卫华,包勇,陈明,张力,李凯新,徐光川,邓小武,卢泰祥,崔念基.诱导化疗和紫杉醇每周同期化疗结合三维适形放射治疗不能手术的Ⅲ期非小细胞肺癌的初步结果[J].癌症,2006,25(10):1279-1283. 被引量:11
  • 2汤钊猷.现代舯瘤学[M].上海:上海科技出版社,1993.629.
  • 3Jett RJ.What's new in Lung Mag Jng system [J].Chest,1997,111(6):1486.
  • 4Pfister DG,Johnson DH,Azzoli CG,et al.American society of clinical oncology treatment of unresecable non-small cell lung cancer guideline:update 2003[J].J Clin Oncol,2004,22:330-353.
  • 5Chen M,Jiang GL,Fu XL,et al.The impact of overall treatment time on outcomes in radiation therapy for nonsmall cell lung cancer[J].Lung Cancer,2000,28(1):11-19.
  • 6Choy H,Akerley W,Safran H,et al.Multiinstitutional phase Ⅱ trial of paclitaxel,carboplatin,and concurrent radiation therapy for locally advanced non-small cell lung cancer[J].J Clin Oncol,1998,16:3316-3322.
  • 7Vokes EE,HerndonJE,Kelley MJ,et al.Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC):initial analysis of a randomized phase Ⅲ trial[J].Proc Am Soc Clin Oncol,2004,22:7005.
  • 8Smith R,Choy H,Curran WJ.Preliminary report of locally advanced multimodality protocol (LAMP):ACR 427:a randomized phase Ⅱ study of three chemo-radiation regimens with paclitaxel,carboplatin,and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC)[J].Proc Am Soc Clin Oncol,2002,20.
  • 9Gervais R,Ducolone A,Lechevalier T,et al.Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT)[vinorelbine (Vr)cisplatine (P)]:Final results of a randomized phase Ⅲ trial in stage Ⅲ unresectable non small cell lung (NSCLC)cancer.Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT[J].Proc Am Soc Clin Oncol,2005,23:7016.
  • 10Albain KS,Crowley JJ,Turrisi AT,et al.Concurrent cisplatin,etoposide and chest radiotherapy in pathology stage Ⅲ B non-small cell lung cancer:a SWOG phase Ⅱ study (SWOG 9019)[J].J Clin Oncol,2002,20:3454-3460.

共引文献57

同被引文献10

  • 1Breathnach OS, Freidlin B, Conley B, el al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small- cell lung cancer: Sobering results[J]. C2in Oncol , 2001,19 (6) : 1734-1742.
  • 2Hillman SL,An MW,O'Connell MJ, el al . Evaluation of the optimal number of lesions needed for tumor evaluation using the responseevaluation criteria in solid tumors: a north cen- tral cancer treatment group investigation[J]. J Clin Oncol , 2009,27(19) :3205-3210.
  • 3Trotti A,Colevas A D,Setser A, et al . CTCAE v3.0:devel- opment of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol , 2003, 13(3) : 176-181.
  • 4Apostolopoulou E, Raftopoulos V, Terzis K, el al . Infection Probability Score, APACHE Ⅱ and KARNOFSKY scoring systems as predictors of bloodstream infection onset in he- matology-oneology patients[J]. BMC Infect Dis , 2010,26 (10) :135.
  • 5Han C, Ma J, Zhao J, et al . EGFR mutations, gene amplifi- cation, and protein expression and KRAS mutations in pri mary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis[J]. Cancer Invest , 2011,29(9) :626-634.
  • 6Ando M, Okamoto I, Yamamoto N, el al. Predictive factors for interstitial lung disease, antitumor response,and survival in non-small-cell lung cancer patients treated with gefitinib [J]. Clin Oncol ,2006,24(16) :2549-2556.
  • 7Azzoli CG, Baker S Jr, Temin S, el al . American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage 1V non small cell lung cancer [J]. Clin Oncol , 2009,27(36) : 6251-6266.
  • 8Reek M, Buehholz E, Romer KS, el al . Gefitinib monothera- py in chemotherapy-naive patients with inoperable stage Ⅲ/ IV non-small-cell lung cancer[J]. Clin Lung Cancer , 2006, 7(6) :406-411.
  • 9Shah NT, Kris MG, Pao W, el al . Practical management of patients with non-small-cell lung cancer treated with ge- fitinib[J].Clin Oncol ,2005,23(1) :165-174.
  • 10Kim E, Hirsh V, Mok T, et al . Gefitinib vs. docetaxel in previously treated non-small-cell lung cancer (INTEREST) a randomised phase HI trial[J]. Lancet , 2008,372 (9652) : 1809-1818.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部